We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Immunoassay System for Mid-sized Labs

By HospiMedica staff writers
Posted on 29 Nov 2005
A new automated clinical immunoassay system designed for use in mid-sized laboratories incorporates many of the functions of larger systems.

The Advia Centaur CP immunoassay system includes many productivity-enhancement features and the same assay methodologies and reagent packs as the Advia Centaur. More...
Both are the products of Bayer HealthCare, Diagnostics Division (Tarrytown, NY, USA). The complete menu of disease state assay groups available on both the Centaur and Centaur CP include cardiovascular, oncology, fertility, and infectious disease testing.

Together with the Advia 1200 clinical chemistry system, the new Centaur CP works with Bayer's Advia CentralLink networking and data management solutions to deliver synergies of sample handling, connectivity, and functionality to provide a complete immunoassay and clinical chemistry solution. This enables smaller labs to offer a complete testing service without costly sample splitting and result collation.

"Our customers have clearly told us that they have a need for an immunoassay platform that packages Advia Centaur immunoassay system technology in a smaller footprint,” noted Tom Warekois, senior vice president of global strategic marketing, Bayer Diagnostics. "The Advia Centaur CP enables the mid-sized and specialty laboratory to make improvements in productivity by consolidating testing onto a single platform sized for their laboratory needs.”




Related Links:
Bayer Diagnostics

Gold Member
12-Channel ECG
CM1200B
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Hybrid Arch Device
Neo EDE
Gold Member
Blood Gas Analyzer
i-Check200
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: New findings show that chemotherapy plus immunotherapy before surgery produced greater tumor destruction than immunotherapy alone in head and neck cancer patients (Image Credit: Adobe Stock)

Combination Therapy Before Surgery Drives Stronger Tumor Reduction in Head and Neck Cancer

Patients with head and neck cancer who are scheduled for surgery often face a waiting period with limited treatment, creating an opportunity to reduce viable tumor burden before the operation.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.